The story of Sildenafil presents a interesting case for observers in the drug sector. While initially a phenomenal success, generating huge profits, the patent end and the subsequent entry of generic versions have significantly impacted revenue. This raises questions about the long-term viability of related therapeutic projects and suggests that si